Highlights from the Ratings and Financial Report for Maravai LifeSciences Holdings Inc. (MRVI) – News Heater
Home  »  Companies   »  Highlights from the Ratings and Financial Report f...

Highlights from the Ratings and Financial Report for Maravai LifeSciences Holdings Inc. (MRVI)

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) went up by 6.14% from its latest closing price compared to the recent 1-year high of $45.79. The company’s stock price has collected 5.74% of gains in the last five trading sessions. Press Release reported 7 hours ago that Maravai LifeSciences To Host Earnings Conference Call on Tuesday, August 10, 2021

>> 7 Top Picks for the Post-Pandemic Economy <<

Is It Worth Investing in Maravai LifeSciences Holdings Inc. (NASDAQ :MRVI) Right Now?

Opinions of the stock are interesting as 9 analysts out of 10 who provided ratings for Maravai LifeSciences Holdings Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $49.33, which is $9.98 above the current price. MRVI currently public float of 89.07M and currently shorts hold a 5.47% ratio of that float. Today, the average trading volume of MRVI was 1.19M shares.

MRVI’s Market Performance

MRVI stocks went up by 5.74% for the week, with a monthly drop of -10.52% and a quarterly performance of 13.07%. The volatility ratio for the week stands at 4.94% while the volatility levels for the past 30 days are set at 4.43% for Maravai LifeSciences Holdings Inc.. The simple moving average for the period of the last 20 days is -0.37% for MRVI stocks with a simple moving average of 15.40% for the last 200 days.

Analysts’ Opinion of MRVI

Many brokerage firms have already submitted their reports for MRVI stocks, with KeyBanc Capital Markets repeating the rating for MRVI by listing it as a “Overweight.” The predicted price for MRVI in the upcoming period, according to KeyBanc Capital Markets is $33 based on the research report published on December 16th of the previous year 2020.

Stifel gave a rating of “Buy” to MRVI, setting the target price at $31 in the report published on December 15th of the previous year.

MRVI Trading at 0.39% from the 50-Day Moving Average

After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.36% of loss for the given period.

Volatility was left at 4.43%, however, over the last 30 days, the volatility rate increased by 4.94%, as shares sank -9.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.02% upper at present.

During the last 5 trading sessions, MRVI rose by +5.74%, in comparison to the 20-day moving average, which settled at $40.06. In addition, Maravai LifeSciences Holdings Inc. saw 43.07% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for MRVI

Current profitability levels for the company are sitting at:

  • +35.52 for the present operating margin
  • +69.29 for the gross margin

The net margin for Maravai LifeSciences Holdings Inc. stands at +27.06. The total capital return value is set at 15.76, while invested capital returns managed to touch 12.79.

Based on Maravai LifeSciences Holdings Inc. (MRVI), the company’s capital structure generated 667.47 points at debt to equity in total, while total debt to capital is 86.97. Total debt to assets is 46.49, with long-term debt to equity ratio resting at 660.69. Finally, the long-term debt to capital ratio is 86.09.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 11.02, with the company’s debt to enterprise value settled at 0.19. The receivables turnover for the company is 8.11 and the total asset turnover is 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.54.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam